PL324905A1 - Application of griseofulvin in carcinoma development inhibition - Google Patents

Application of griseofulvin in carcinoma development inhibition

Info

Publication number
PL324905A1
PL324905A1 PL96324905A PL32490596A PL324905A1 PL 324905 A1 PL324905 A1 PL 324905A1 PL 96324905 A PL96324905 A PL 96324905A PL 32490596 A PL32490596 A PL 32490596A PL 324905 A1 PL324905 A1 PL 324905A1
Authority
PL
Poland
Prior art keywords
griseofulvin
application
development inhibition
carcinoma development
carcinoma
Prior art date
Application number
PL96324905A
Other languages
English (en)
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PL324905A1 publication Critical patent/PL324905A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL96324905A 1995-08-03 1996-07-30 Application of griseofulvin in carcinoma development inhibition PL324905A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US183995P 1995-08-03 1995-08-03
US67418196A 1996-07-16 1996-07-16

Publications (1)

Publication Number Publication Date
PL324905A1 true PL324905A1 (en) 1998-06-22

Family

ID=26669547

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96324905A PL324905A1 (en) 1995-08-03 1996-07-30 Application of griseofulvin in carcinoma development inhibition

Country Status (16)

Country Link
EP (1) EP0841914A2 (es)
JP (1) JPH11511136A (es)
KR (1) KR19990036137A (es)
AR (1) AR003176A1 (es)
AU (1) AU713031B2 (es)
BR (1) BR9609920A (es)
CA (1) CA2228503A1 (es)
CZ (1) CZ30598A3 (es)
HU (1) HUP9903506A3 (es)
IL (1) IL123094A0 (es)
MX (1) MX9800945A (es)
NO (1) NO980420L (es)
PL (1) PL324905A1 (es)
SK (1) SK14298A3 (es)
TR (1) TR199800244T2 (es)
WO (1) WO1997005870A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
DK1098641T3 (en) * 1998-07-27 2016-08-15 St Jude Pharmaceuticals Inc Chemically induced intracellular hyperthermia
AU761844C (en) 1998-11-09 2004-09-23 F. Hoffmann-La Roche Ag Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
CN1543356B (zh) * 2001-06-25 2011-09-28 味之素株式会社 抗肿瘤剂
EP2008652A1 (en) * 2007-06-28 2008-12-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
EP2204367A1 (en) 2008-12-22 2010-07-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering

Also Published As

Publication number Publication date
AU6683496A (en) 1997-03-05
KR19990036137A (ko) 1999-05-25
SK14298A3 (en) 1998-09-09
HUP9903506A2 (hu) 2000-06-28
IL123094A0 (en) 1998-09-24
AU713031B2 (en) 1999-11-18
NO980420L (no) 1998-04-03
CA2228503A1 (en) 1997-02-20
TR199800244T2 (xx) 1998-09-21
NO980420D0 (no) 1998-01-30
WO1997005870A2 (en) 1997-02-20
MX9800945A (es) 1998-04-30
AR003176A1 (es) 1998-07-08
EP0841914A2 (en) 1998-05-20
HUP9903506A3 (en) 2000-07-28
BR9609920A (pt) 1999-07-06
JPH11511136A (ja) 1999-09-28
CZ30598A3 (cs) 1998-06-17
WO1997005870A3 (en) 1997-04-17

Similar Documents

Publication Publication Date Title
PL324905A1 (en) Application of griseofulvin in carcinoma development inhibition
PL324904A1 (en) Application of fluconazole in carcinoma development inhibition
GB2298422B (en) Compounds and their use
EP0794789A4 (en) PRENYL TRANSFERASE INHIBITORS
EP1009415A4 (en) INHIBITORS OF $ g (b) -LACTAMASES AND THEIR USES
GB2299506B (en) Antiperspirant actives and compositions
PL323904A1 (en) C-4' modified inhibitors of andenosinic kinase
IL122428A0 (en) Minizymes and minribozymes and uses thereof
IL117859A (en) Isothiazolones and their uses
GB9521125D0 (en) Cosmetic composition
GB9511938D0 (en) Cosmetic composition
GB9526560D0 (en) Use of 2-Amino-Heterocycles
PL323866A1 (en) Application of derivatives of vitamin d4 in treating carcinoma
GB9525812D0 (en) Composition and use
PL324888A1 (en) Application of derivatives of 1,2,4-triazole in carcinoma development inhibition
EP0831920A4 (en) NOVEL CATHEPSIN AND METHODS AND COMPOSITIONS FOR INHIBITING CATHEPSIN
EG21286A (en) Blends of organosillane compounds and their use
ZA964605B (en) Inhibition of exoprotein in absorbent article
HUP9801158A3 (en) Imidazole derivatives and medicinal composition thereof
ZA96725B (en) Use of phenyclyclohexylcarboxamides
GB9507297D0 (en) New composition of matter
EP0733365A3 (en) Use of benzoquinolin-3-one for the treatment and prevention of prostate cancer
GB9510563D0 (en) Well inhibition
ZA963825B (en) Composition of matter
GB9523843D0 (en) Cosmetic composition and method